Roubaix Capital LLC Acquires New Shares in Certara, Inc. $CERT

Key Points

• Roubaix Capital LLC acquired 269,071 shares of Certara, Inc., valued at approximately $2.66 million, representing about 0.17% of the company's stock by the end of the quarter.
• The company reported $0.07 EPS for the last quarter, missing estimates by $0.03, with revenue of $104.57 million showing a 12.1% year-over-year increase.
• Certara has received varying ratings from analysts, with a consensus target price of $15.14 and an average rating of "Moderate Buy" from eight investment analysts.

Roubaix Capital LLC bought a new stake in Certara, Inc. (NASDAQ:CERT - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 269,071 shares of the company's stock, valued at approximately $2,664,000. Roubaix Capital LLC owned 0.17% of Certara at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in CERT. Versant Capital Management Inc increased its position in Certara by 218.8% in the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after acquiring an additional 1,866 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in Certara in the 1st quarter valued at approximately $31,000. Wells Fargo & Company MN increased its position in Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after acquiring an additional 1,047 shares during the period. Johnson Financial Group Inc. bought a new position in Certara during the 4th quarter valued at $47,000. Finally, Sterling Capital Management LLC boosted its stake in Certara by 57.2% during the 4th quarter. Sterling Capital Management LLC now owns 7,209 shares of the company's stock valued at $77,000 after purchasing an additional 2,624 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on CERT shares. Morgan Stanley started coverage on Certara in a research note on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 price objective for the company. Barclays raised Certara from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $11.00 to $14.00 in a research note on Thursday, May 8th. JMP Securities reissued a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. UBS Group reduced their price objective on Certara from $17.50 to $15.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Finally, KeyCorp reduced their price objective on Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a research note on Monday, July 14th. Five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Certara has an average rating of "Moderate Buy" and a consensus price target of $15.14.

Certara Stock Up 6.0%

Shares of Certara stock traded up $0.65 during midday trading on Friday, hitting $11.42. The company's stock had a trading volume of 422,892 shares, compared to its average volume of 1,703,952. The firm has a market capitalization of $1.83 billion, a P/E ratio of 228.45 and a beta of 1.42. The stock has a 50-day simple moving average of $10.79 and a 200-day simple moving average of $11.60. The company has a quick ratio of 2.16, a current ratio of 2.16 and a debt-to-equity ratio of 0.27. Certara, Inc. has a 1-year low of $8.64 and a 1-year high of $15.69.

Certara (NASDAQ:CERT - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $104.57 million during the quarter, compared to analyst estimates of $104.14 million. Certara had a return on equity of 5.11% and a net margin of 1.97%.The business's quarterly revenue was up 12.1% on a year-over-year basis. During the same period last year, the business earned $0.07 EPS. As a group, sell-side analysts expect that Certara, Inc. will post 0.28 earnings per share for the current year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.